Cheryl A. Sadow, MD Director, Tumor Metric Service
The Tumor Metric Service provides formal interpretations and consultations for a variety of clinical investigative trials that involve radiology. Interpretations and consultations are provided for clinical research organizations (CROs) who contract with the BWH Department of Radiology for this work. In addition, interpretations and consultations are provided for the Tumor Imaging Metric Core, an internal division of the Dana-Farber/Harvard Cancer Center that conducts clinical trials within the Harvard teaching hospitals. While most clinical trials are for oncologic indications, others are for non-neoplastic conditions such as renal stone evaluation, endometriosis, and polycystic kidney disease. Radiologists apply trial-specific criteria for imaging assessment using a variety of response criteria including RECIST/RECIST 1.1, Revised Response Criteria for Malignant Lymphoma, Prostate Cancer Working Group 2, and Immune Response-Related Criteria (irRC) among others. Volumetric measurements are made in several trials, as indicated for tumor volumes or organ volumes in conditions such as polycystic kidney disease and hematopoietic disorders such as myelofibrosis and polycythemia vera.